108 results about "Adenomyosis" patented technology

The invention provides devices, systems and methods for reducing or abolishing blood flow by occluding uterine arteries for treating adenomyosis and endometriosis. A non-invasive uterine artery occlusion device embodying features of the invention includes a pair of pressure-applying members with opposed tissue-contacting surfaces, a supporting shaft configured to adjust the distance between tissue-contacting surfaces, and at least one sensor for locating a uterine artery disposed on at least one pressure-applying member. Uterine arteries are occluded by indirectly compressing the artery by compressing tissue near to an artery. One uterine artery may be occluded or both may be occluded simultaneously. A uterine artery may be accessed via a body cavity, such as a patient's vagina, and may be occluded by compressing a portion of the vaginal wall around a portion of a uterine artery.

The present invention provides a vaginally administrable tablet useful for treating leiomyomata, leiomyoma, myoma, uterine fibroids, endometriosis, adenomyosis and other related disorders. The tablet comprises mifepristone, at least one non-effervescent excipient or diluent, and at least one effervescent excipient.

The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, oneor more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.

This invention provides a medicinal composition for treatment of endometriosis and its preparation method and its controlling method. This medicinal composition is prepared by using the medical ingredients of common peony root, Chinese angelica root, cattail pollen, chuanxiong ligusticum rhizome, cassiabarktree twig, yanhusuo rhizome, Chinese thorowax root, membranous milkvetch root, malaytea scurfpea fruit and myrrh. Curative effectiveness of this medical composition in treating endometriosism is definitude with fast action but without toxin and side effects.

The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

The invention discloses a 1,2,3-trihydroxy benzene and derivant or pharmacy acceptable salt for zinc ion metal-prolease inhibition, which is characterized by the following: theses compounds is used for selective depressant of zinc ion metal-prolease (such as MT1-MMP, gelatinase A, B and collagenase, matrilysins, metal-elastase and stromelysin-1); these depressants can adjust physiological and pathology course with MMPs, ADAMs, ADAM-TS such as vessel rebirth, wound healing, organ transplantation, fecundation course and reactivation capability, rebuilding bone and ache, which is used for treating cancer, cardiovascular disease, arthritis, periodontal disease, multiple sclerosis, inflammation, adenomyosis, cornea ulcer, bacterial meningitis, diabetic syndrome, kidney disease, nerve retrogression disease, AIDS, bleb, anaphylaxis, adenomyosis, osteoporosis, asthma and so on; theses blocking agents can be used for antisenescence, antibiosis, commercial manufacture addition agent of cell epimatrix, collagen product, cosmetics and make-up preparation, which can used for animals and other living bodies.

The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

The present invention is directed to neutralizing prolactin receptor antibodies 002-H06 and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

The invention relates to the technical field of medicines, and in particular to an application of an interleukin (IL-22) antibody in preparing medicines for treating adenomyosis (AD). According to the application provided by the invention, on the basis of research experiments that an angiogenesis promoting effect of endometrial ESC (endometrial stromal cell) of the AD can be inhibited by antagonizing the IL-22 and pathogenesis and progress of the AD can be inhibited subsequently, potential values of antagonizing the IL-22 (such as an IL-22 neutralizing antibody) in treating the AD is further assessed. Based upon results of in vitro experiments and in vivo animal tests, it is displayed that the IL-22 neutralizing antibody, which can take an obvious therapeutic effect on the adenomyosis, can be further used for preparing the medicines for treating the adenomyosis.

The invention relates to an oriental blueberry fruit powder health product composition as well as a preparation method and application thereof, and belongs to the technical field of health products. The oriental blueberry fruit powder health product composition comprises the following components in parts by weight: 70-75 parts of oriental blueberry fruit powder, 16-20 parts of cassava starch, 7-9 parts of maltodextrin and 0.3-0.6 part of magnesium stearate. Verified by multiple experiments, the oriental blueberry fruit powder health product composition disclosed by the invention has good effects of repairing cell damages as well as maintaining beauty and keeping young by virtue of reasonable combination, is extremely wide in application prospects of products, and can be used for treating polycythemia, thyroid nodule, ovarian cysts, alcoholic liver diseases, fatty liver and adenomyosis of uterus; related reports of the effects are not provided in the field; and in addition, the preparation method of the oriental blueberry fruit powder disclosed by the invention is simple and reliable, ensures that anthocyanin and other nutritional components in oriental blueberry fruit can be effectively kept without being damaged, and is easy in popularization and application.

The invention discloses a traditional Chinese medicine preparation for adenomyosis of uterus. The traditional Chinese medicine preparation for the adenomyosis of uterus is prepared by taking astragalus membranaceus, radix paeoniae rubra, earthworm, ligusticum wallichii, fennel, dried ginger, angelica sinensis, peach kernel, flos carthami, fructus aurantii, corydalis tuber, trogopterus dung, cortex moutan, lindera aggregata, rhizome cyperi, Szechwan chinaberry fruit, pollen typhae, scorpion, rhizome sparganii, curcuma zedoary, resina draconis, pangolin and spina gleditsiae as the raw medicines, preprocessing the raw medicines through cleaning and slicing according to different characteristics of the raw medicines, and performing proportional preparation and manufacturing through a special method. The traditional Chinese medicine for the adenomyosis of uterus achieves the effects of soothing the liver, regulating qi, promoting blood circulation, removing blood stasis, eliminating pathogens, strengthening body energy, warming channels and expelling cold. The traditional Chinese medicine preparation for the adenomyosis of uterus is unique in composition and manufacturing method, and through clinical verification, is significant in treating effects, short in treatment cycle, low in price and free from toxic and side effects, thereby having a wide market application prospect.

The invention relates to a pharmaceutical composition for treating dysmenorrhea, and a preparation method thereof, belonging to the field of traditional Chinese medicines. The pharmaceutical composition comprises the following raw materials in parts by weight: 10-20 parts of rhizoma sparganii, 10-20 parts of rhizoma curcumae, 10-20 parts of cortex moutan radicis, 7-13 parts of cortex cinnamomi, 20-30 parts of rhizoma corydalis, 10-20 parts of radix linderae, 10-20 parts of artemisia anomala, 10-20 parts of radix angelicae sinensis, 20-30 parts of radix paeoniae alba, 20-30 parts of radix rehmanniae preparata, 20-30 parts of rhizoma cyperi, 10-20 parts of semen persicae, and 0.5-1.5 parts of scolopendra. The pharmaceutical composition can warm channels and expel cold, remove blood stasis and relieve pain, is used for qi-stagnation and blood stasis type adenomyosis dysmenorrhea, has the advantages of low cost, high efficacy, safety and reliability in the aspect of treating dysmenorrhea,thus being worthy of further popularization and use clinically.

The present invention relates to substituted Pyridyl-cycloalkyl- carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis.

A Chinese medicine for treating endometriosis, abdominal pain with straining before mensis, menoxenia, intestinal adhesion after operation, chronic appendicitis, etc and its preparing process are disclosed.

The invention discloses an application of a traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea. The traditional Chinese medicine composition comprises 30g of Chinese angelica, 30g of motherwort herbs, 15g of fried cattail pollen, 10g of Sichuan lovage rhizome, 15g of flying squirrels droppings, 10g of red peony roots, 10g of cassia twigs, 10g of largehead atractylodes rhizome, 10g of Indian bread, 10g of peach kernels and 10g of red flowers, water is added into the mixture with the volume of 8 times of total weight of medical materials and 6 times of total weight of the medical materials respectively every time, the mixture is decocted and boiled for two times in the water, then filter liquids are combined, and the decompressed concentrated water is extracted. According to the application of the traditional Chinese medicine composition in preparing the drugs for treating the secondary dysmenorrheal, on the basis of differentiation and treatment theories of traditional Chinese medical science, the traditional Chinese medicine composition is formed by combining a plurality of years of clinical experience; on the basis that three parts of analgesia prescriptions before menstruation are used to treat primary dysmenorrheal, the peach kernels and the red flowers are added and have obvious curative effects in treating the secondary dysmenorrheal caused by endometriosis, adenomyosis, pelvic inflammation and the like, and particularly, the curative effect in treating the secondary dysmenorrheal caused by the endometriosis reaches 96.4%.

The invention discloses a traditional Chinese medicine composition for treating adenomyosis. The traditional Chinese medicine composition consists of the following components in parts by weight: 8-12 parts of semen cuscutae, 8-12 parts of placenta hominis, 8-12 parts of angelica sinensis, 4-8 parts of ligusticum wallichii, 8-12 parts of corydalis tuber, 4-8 parts of pericarpium citri reticulatae viride, 8-12 parts of Chinese herbaceous peony and 13-17 parts of winged euonymus twig. The invention also discloses a preparation method and application of the traditional Chinese medicine composition. Through clinical observation and study, people find that the traditional Chinese medicine composition has specific clinical treatment effect for patients suffering from adenomyosis, including the effect of effectively relieving progressive dysmenorrheal exacerbation of patients, reducing too much menstrual blood volume, shrinking uterus volume and lowering traditional Chinese medicine syndrome aggregate score. The traditional Chinese medicine composition can be used for a long time with little side reaction, and can be further developed to be new traditional Chinese medicine for treating adenomyosis.

The invention discloses a capsule for eliminating an illness and removing stasis and a preparation method thereof. Manis pentadactyla, semen momordicae and edible tulip have the effects of invigorating blood circulation, removing stasis, eliminating illness and removing stasis, and directly guiding blood to lesions by main channels; curcuma zedoary, radix curcumae, toosendan fruit, felwort, moutan bark, immature bitter orange, pericarpium citri reticulatae viride, lysimachia christinae hance, radices trichosanthis and seed of job's tears have the effects of soothing the liver, regulating the flow of vital energy, clearing away heat and toxic materials, diminishing inflammation, promoting dieresis, balancing internal organs, and moderating yin and yang; rheum officinale, asarum and rhizoma alismatis have the effects of clearing toxins, regulating vital energy and blood, and dredging the six hollow organs; radix sophorae flavescentis and sculellaria barbata have the effects of diminishing inflammation, promoting dieresis and resisting tumors; therefore, all the components are used together to achieve the effects of promoting blood circulation to remove blood stasis, eliminating illness, removing stasis, clearing away heat and toxic materials, soothing the liver, regulating the flow of vital energy, smoothing internal organs, and resisting inflammation and tumors. Therefore, the capsule has a definite treatment effect on mastopathy, hyperplasia of mammary glands, a stomachache, a breast distending pain, adenomyosis of uterus, ovarian cyst, pelvic inflammation and annexitis; the recovery rate can be over 90%.

The present invention relates to a novel compound useful as a TRPV4 antagonist, specifically the compound 1-(((5S,7R)-3-(5-cyclopropylpyrazin-2-yl)-7-hydroxy-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compound. The compound of the invention can be useful in the treatmentof a disease state selected from: atherosclerosis, disorders related to vasogenic edema, postsurgical abdominal edema, ocular edema, cerebral edema, local and systemic edema, fluid retention, sepsis,hypertension, inflammation, bone related dysfunctions and congestive heart failure, pulmonary disorders, chronic obstructive pulmonary disorder, ventilator induced lung injury, high altitude inducedpulmonary edema, acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, sinusitis/rhinitis, asthma, cough; including acute cough, sub-acute cough and chronic cough, pulmonary hypertension, overactive bladder, cystitis, pain, motor neuron disorders, genetic gain of function disorders, cardiovascular disease, renal dysfunction, stroke, glaucoma, retinopathy, endometriosis, pre-term labor, dermatitis, pruritus, pruritus in liver disease, diabetes, metabolic disorder, obesity, migraine, pancreatitis, tumor suppression, immunosuppression, osteoarthritis, crohn's disease, colitis, diarrhea, intestinal irregularity (hyperreactivity/hyporeactivity), fecal incontinence, irritable bowel syndrome (IBS), constipation, intestinal pain and cramping, celiac disease, lactose intolerance, and flatulence.

The invention relates to pharmacy. It is an object of the present invention to produce nanomicellar structures containing EGCG and achieving a positive result consisting in increasing bioavailability in peroral administration. The object of this invention is achieved by a new pharmaceutical composition for peroral administration containing epigallocatechin-3-gallate as the active component and a target additive that is a block copolymer of oxyethylene and oxypropylene, in which the content of the hydrophobic block is less than 50% by mass and the hydrophilic block has a molecular weight of 2,250 daltons or more at a ratio of the block copolymer to the active component ranging from 1:1 to 10:1. The composition improves absorption of the active compound by the blood flow when delivered perorally.

The invention particularly relates to a method for screening pharmacodynamic substances for treating adenomyosis in cassia twig and poria cocos pills. A classic famous prescription cassia twig and poria cocos pill is an important medicine for clinically treating adenomyosis. The effective components in the cassia twig and poria cocos pills are not clear, so that the method has important significance in screening pharmacodynamic material basis in the cassia twig and poria cocos pills. Based on a spectrum-effect research technology, chromatographic peak information of extract components in cassia twig and poria cocos pills is collected through HPLC and GC analysis, the expression level of VEGF, TNF-alpha and bcl-2 cytokines in an in-vitro cell model is detected to determine the drug effect level, and the extract components with good drug effects are screened through correlation analysis. According to the screening method provided by the invention, 24 potential substances for treating AMby GFW are screened out, an experimental basis is provided for development and clinical application of GFW new drugs, a 'multi-dimensional spectrum-multiple effect-multiple method association' spectrum-effect research mode is preliminarily formed, and a technical support and a research thought are provided for basic identification of pharmacodynamic substances of traditional Chinese medicines.